SeaStar Medical wins FDA Breakthrough Device designation for SCD sepsis therapy

FDA granted Breakthrough Device Designation for SeaStar Medical’s SCD therapy targeting hyperinflammation in adult sepsis patients, supporting an accelerated pathway as NEUTRALIZE-AKI pivotal trial data are prepared.